Faeth Therapeutics Gestione

Criteri Gestione verificati 0/4

Faeth Therapeutics Il CEO è Anand Parikh, nominato in Jun2026, ha un mandato di meno di un anno. possiede direttamente 3.17% delle azioni della società, per un valore di $ 23.57M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.5 anni e 0.4 anni.

Informazioni chiave

Anand Parikh

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	3.2%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Nov 03

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Articolo di analisi • Jul 02

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Articolo di analisi • Mar 14

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Articolo di analisi • Aug 14

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Seeking Alpha • Aug 09

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics press release (NASDAQ:SNSE): Q2 GAAP EPS of -$0.34 beats by $0.06. Cash, cash equivalents and marketable securities were $123.7 million as of June 30, 2022, as compared to $147.6 million as of December 31, 2021. Sensei expects its current cash balance to fund operations into the first quarter of 2025.

Articolo di analisi • Apr 18

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Articolo di analisi • Nov 16

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

AMMINISTRATORE DELEGATO

Anand Parikh (40 yo)

less than a year

Mandato

Mr. Anand Parikh, Esq., J.D., served as Chief Operating Officer and Director at Sensei Biotherapeutics, Inc. from February 17, 2026 and serves as its Chair since 2026 and serves as its Chief Executive Offi...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Josiah Craver	Senior VP of Finance	1.8yrs	US$409.71k	0% $ 0
Christopher Gerry	General Counsel & Secretary	4yrs	US$434.60k	0.0037% $ 27.5k
Anand Parikh	CEO, President & Chair	less than a year	Nessun dato	3.17% $ 23.6m
Siddhartha Mukherjee	Scientific Co-Founder	less than a year	Nessun dato	Nessun dato
Lewis Cantley	Scientific Co-Founder	less than a year	Nessun dato	Nessun dato
Scott Lowe	Scientific Co-Founder	less than a year	Nessun dato	Nessun dato
Gregory Hannon	Scientific Co-Founder	less than a year	Nessun dato	Nessun dato
Karen Vousden	Scientific Co-Founder	less than a year	Nessun dato	Nessun dato
Oliver Maddocks	Co-Founder & Chief Scientific Officer	less than a year	Nessun dato	Nessun dato
Benjamin Hopkins	Scientific Co-Founder	less than a year	Nessun dato	Nessun dato
Simon Knott	Scientific Co-Founder	less than a year	Nessun dato	Nessun dato
Marcus Goncalves	Scientific Co-Founder	less than a year	Nessun dato	Nessun dato

0.5yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di FTH non è considerato esperto (durata media 0.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Anand Parikh	CEO, President & Chair	less than a year	Nessun dato	3.17% $ 23.6m
Robert Holmen	Independent Director	9.5yrs	US$62.22k	0.0050% $ 36.9k
Phillip Donenberg	Independent Director	less than a year	Nessun dato	0% $ 0
Richard Ulevitch	Member of Immuno-Oncology Advisory Board	5.2yrs	Nessun dato	Nessun dato
Robert Schreiber	Member of Immuno-Oncology Advisory Board	no data	Nessun dato	Nessun dato
Sona Saira Ramasastry	Director	less than a year	Nessun dato	Nessun dato
Stephen Hahn	Director	less than a year	Nessun dato	0.17% $ 1.3m
Alain Algazi	Member of Immuno-Oncology Advisory Board	no data	Nessun dato	Nessun dato
Daniel Sterman	Member of Immuno-Oncology Advisory Board	no data	Nessun dato	Nessun dato
Maura Gillison	Member of Immuno-Oncology Advisory Board	5.2yrs	Nessun dato	Nessun dato
Sara Pai	Member of Immuno-Oncology Advisory Board	no data	Nessun dato	Nessun dato

0.4yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di FTH non è considerato esperto (durata media del mandato 0.4 anni), il che suggerisce un nuovo consiglio.

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/07/31 02:26
Prezzo dell'azione a fine giornata	2026/07/31 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Faeth Therapeutics, Inc. è coperta da 14 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Jack Allen	Baird
Zhiqiang Shu	Berenberg
Suranjit Mukherjee	BTIG

Faeth Therapeutics Gestione

Criteri Gestione verificati 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chief Financial Officer recently bought US$406k worth of stock

Less than half of directors are independent

Sensei Biotherapeutics, Inc. Appoints Brian Stephenson as Chief Financial Officer, Effective June 12, 2026

Insider recently sold US$501k worth of stock

Sensei Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2026

Sensei Biotherapeutics, Inc. Announces Directorate Appointments, Effective February 13, 2026

Recent updates

Chief Financial Officer recently bought US$406k worth of stock

New major risk - Shareholder dilution

Faeth Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Less than half of directors are independent

Sensei Biotherapeutics, Inc. Appoints Brian Stephenson as Chief Financial Officer, Effective June 12, 2026

Insider recently sold US$501k worth of stock

New major risk - Revenue and earnings growth

New major risk - Negative shareholders equity

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

Sensei Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2026

Sensei Biotherapeutics, Inc. announced that it expects to receive $199.994578 million in funding from The B Group, Inc., Balyasny Asset Management L.P., Columbia Threadneedle Investments NA, Cormorant Asset Management, LP, Fairmount Co, Logos Capital LLC, Vivo Capital LLC and other investors.

Sensei Biotherapeutics, Inc. Announces Directorate Appointments, Effective February 13, 2026

New major risk - Market cap size

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in Pd-(L)1 Resistant Tumors At the Esmo Congress 2025

New major risk - Share price stability

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug At the European Society for Medical Oncology Congress 2025

Sensei Biotherapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Price target increased by 17% to US$4.50

Sensei Biotherapeutics, Inc., Annual General Meeting, May 21, 2025

Insufficient new directors

New minor risk - Share price stability

Sensei Biotherapeutics, Inc. Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Price target decreased by 8.8% to US$3.88

Nasdaq Grants Second Extension Till July 7, 2025 to Sensei Biotherapeutics to Regain Compliance with Minimum Bid Price Requirement

Sensei Biotherapeutics, Inc. to Close its Research Site in Rockville, Maryland and Reduce its Workforce by Approximately 46%

Sensei Biotherapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(a)(1)

Price target decreased by 13% to US$4.33

Sensei Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

New minor risk - Share price stability

Sensei Biotherapeutics, Inc. Announces Management Changes

High number of new directors

Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc. (NasdaqGM:SNSE).

Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting

Sensei Biotherapeutics Receives Non-Compliance Notice from Nasdaq

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo

Sensei Biotherapeutics, Inc. Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Sensei Biotherapeutics, Inc., Annual General Meeting, Jul 10, 2023

Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

High number of new directors

eSensei Biotherapeutics, Inc. Announces Reduction of Total Workforce

Sensei Biotherapeutics, Inc. Announces Executive Changes

High number of new and inexperienced directors

Sensei Biotherapeutics, Inc. Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Apeiron Investment Sends a Letter to Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Sensei Biotherapeutics, Inc. Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, A Ph-Selective Vista-Blocking Antibody

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) dropped from Russell 2500 Value Index

Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer

Price target decreased to US$8.00

High number of new and inexperienced directors

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Price target decreased to US$11.00

Chairman of The Board recently bought US$80k worth of stock

Chairman of The Board recently bought US$136k worth of stock

Chairman of The Board recently bought US$53k worth of stock

Independent Director recently bought US$57k worth of stock

Independent Director recently bought US$250k worth of stock

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer recently sold US$568k worth of stock

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) dropped from Russell 3000E Growth Index

Sensei Biotherapeutics, Inc. Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck

Sensei Biotherapeutics, Inc. announced that it has received $34.5 million in funding from a group of investors